DE-PRESCRIBING MEDICATIONS IN OLDER ADULTS WITH DEMENTIA
Dr Daniel Hoyle
Senior Lecturer, Therapeutics and Pharmacy Practice
School of Pharmacy and Pharmacology,
University of Tasmania, Australia
RESEARCHER PROFILE
Filmed in Hobart, Tasmania, Australia | January 2025
Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.
He earned his PhD from the University of Tasmania in 2020, where his doctoral research examined the clinical and economic outcomes of psychotropic deprescribing within the multidisciplinary “Reducing Use of Sedatives” project implemented across 150 Australian aged care homes. This research has received several accolades, including First Place in the International Psychogeriatric Association Junior Research Awards in 2019.
Currently, Dr. Hoyle leads several projects, including research aimed at improving anticoagulant use in older individuals with dementia and atrial fibrillation using national primary care provider datasets, and the implementation of a hospital-based antipsychotic stewardship program for patients with dementia and/or delirium.
A current project is Geriatric Antipsychotic Stewardship (GApS) Program for Behavioural and Psychological Symptoms of Dementia and Delirium. This program is funded by the Royal Hobart Hospital Research Foundation through an Incubator Grant.
Additionally, Dr. Hoyle serves as an investigator within an educational intervention aimed at improving anticholinergic prescribing in hospitals. Dr. Hoyle is a guest editor with Pharmacy MDPI and holds elected positions on the Australian Deprescribing Network Executive Committee and the Pharmaceutical Society of Australia’s Tasmanian Branch Committee.
https://orcid.org/0000-0003-2867-3736
-
Clinical guidelines for diagnostics and early intervention in Primary Aldosteronism
Primary Aldosteronism (PA), or Conn Syndrome, is the most commonly under-diagnosed cause of high blood pressure affecting millions of people. Associate Professor Jun Yang’s goal is to facilitate the diagnosis of every case of PA and make treatment widely available to all communities including the disadvantaged.
-
Impact of NextSense Institute Research in the field of sensory disabilities
NextSense has a 165 year history of providing services and education for individuals with sensory impairments. With the support of donations, NextSense provides vital support for children and adults, more cochlear implants than any other service in Australia, and is a world leader for research, technology and professional education in the fields of visions and hearing loss.
NextSense clinicians are actively involved in a number of leading research projects—both independently and in collaboration with local and international organisations. The NextSense Institute, part of NextSense is Australia’s leading centre for research and professional education in the field of sensory disabilities.
-
Relationship between language-literacy skills and mental health
In an innovative move towards enhancing mental health services, Associate Professor Amanda Neil and team, supported by the RHH Research Foundation, are undertaking a crucial study on language-literacy skills of patients within mental health care settings. This year-long project, which commenced in April 2024, seeks to unravel to what extent, where and for whom language-literacy skills are being considered in Tasmanian mental health service provision.
